| Patient | Pierre Le Moyne d'Iberville |
|---|---|
| Date of birth | 1982-07-16 |
| Identifiers | MRN HR-ET014-SYN; SSN (made up) 000-14-7260 |
| Document date | 2026-10-13 |
| Author | Marguerite Delacroix-Boateng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Pre-departure review before a naval deployment to French Guiana and the French Antilles. [S]
Mr. Le Moyne d'Iberville returns about three months before the squadron sails. He had a sore arm for a day after the vaccines and nothing else. He has had no fever since his malaria treatment seven months ago. He will be aboard ship for the crossing and in the islands, then ashore near Cayenne and Kourou, possibly with river work inland where malaria is transmitted. He will be responsible for the health measures of his crews and wants to set the example. He asked what he should carry. [S]
| Element | Detail |
|---|---|
| Vaccine reactions | Sore arm for a day |
| Malaria | No fever in seven months |
| Itinerary | Sea crossing, the Antilles, then French Guiana with possible inland river work |
| Question | What to carry and how to protect his crews |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Gastrointestinal | Negative | No diarrhea |
| Psychiatric | Negative | Busy but well |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food | 1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total) | Oral route | 2026-03-03 to 2026-03-05 | completed | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days | 30 mg base once daily for 14 days | Oral route | 2026-03-03 to 2026-03-16 | completed | S |
| Atovaquone-proguanil 250 mg/100 mg tablet: one tablet daily with food, starting one to two days before entering a malaria area, daily there, and for seven days after leaving | once daily from 1 to 2 days before until 7 days after the malaria areas | Oral route | 2026-10-13 | on-hold | S |
| Azithromycin 500 mg tablet: one tablet daily for up to three days for severe travelers' diarrhea (standby supply) | once daily for up to 3 days if needed | Oral route | 2026-10-13 | on-hold | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) daily with food for 14 days, starting when he leaves the malaria areas (terminal prophylaxis) | 30 mg base once daily for 14 days after leaving the malaria areas | Oral route | 2026-10-13 | on-hold | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-13 | Body height | 175 | cm | S |
| 2026-10-13 | Body weight | 69.2 | kg | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-10-13 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-10-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-13 | Heart rate | 64 | /min | S |
| 2026-10-13 | Respiratory rate | 14 | /min | S |
| 2026-10-13 | Body temperature | 36.6 | Cel | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-13 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-10-13 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
Vital signs recorded on 2026-10-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; temperature 36.6 C, blood pressure 122/76, pulse 64, weight 69.2 kg |
| Abdomen | Spleen not palpable |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requested | resolved | confirmed | R50.9 | S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation. |
| Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PD | resolved | confirmed | B51.9 | S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic. |
| Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccines | active | confirmed | Z71.84 | S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705. |
| Small cutaneous abscess of the right forearm, about 2 cm, from a wooden splinter in the dockyard, without fever, spreading cellulitis or systemic signs; drained, without antibiotics; methicillin-susceptible Staphylococcus aureus on culture; resolved | resolved | confirmed | L02.413 | S — Synthetic acute problem; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Relapse surveillance and the fever action plan | Every visit | Completed today | No fever in seven months; plan extended to travel and after return |
| Laboratory | Pre-departure blood count | Once, before a long deployment | Completed today | Hemoglobin 14.1 g/dL, platelets 236 x10^3/uL |
| Medication safety | Malaria chemoprophylaxis choice, dosing and interactions | Before travel | Completed today | Atovaquone-proguanil prescribed; no interacting medicines; take with food |
| Medication safety | Terminal prophylaxis (presumptive antirelapse therapy) for prolonged P. vivax exposure | After leaving the malaria areas | Completed today | Primaquine 30 mg base daily for 14 days prescribed, G6PD normal |
| Examination | Yellow fever certificate valid on arrival | Before travel | Up to date | Vaccinated eleven weeks ago; certificate valid |
| Examination | Hepatitis B vaccine series | Two doses one month apart | Completed today | HepB-CpG dose 2 today |
| Examination | Hepatitis A vaccine dose 2 | Six to twelve months after dose 1 | Due | Due after the deployment; dose 1 gives protection for the trip |
| Examination | Influenza vaccine | Each season | Completed today | Given today |
| Self-management | Vector avoidance for dengue, chikungunya and typhus | Before and during travel | Completed today | Repellent, permethrin-treated clothing, nets, screens; flea and lice control aboard; no dengue vaccine is recommended for travelers |
| Examination | Chikungunya vaccine | Before travel, if an outbreak notice applies | Due | CDC lists a chikungunya outbreak in French Guiana and recommends vaccination for travelers to outbreak areas; to be decided at a short visit a month before departure against the notice then current |
| Self-management | Food and water precautions and travelers' diarrhea self-treatment | Before travel | Completed today | Advice given; standby azithromycin prescribed |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Influenza vaccine, inactivated, trivalent, preservative-free [S]
Guideline basis: CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Yellow Fever (2026); French Guiana (France): travel health destination page (yellow fever and malaria information updated April 2025) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Dengue (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Rickettsial Diseases (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Travelers' Diarrhea (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006)
Follow-up: Short visit a month before departure for the chikungunya vaccine decision. Post-travel visit on return, sooner for any fever. [S]